Merck (MRK) Share-based Compensation (2009 - 2026)

Merck (MRK) has 18 years of Share-based Compensation data on file, last reported at $185.0 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $185.0 million, down 5.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $810.0 million (up 3.85% YoY), and the FY2025 annual result was $820.0 million, up 7.75% from the prior year.
• Share-based Compensation eased to $185.0 million in Q1 2026 per MRK's latest filing, from $205.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $216.0 million in Q2 2025 and troughed at $120.0 million in Q1 2022.
• A 5-year average of $173.6 million and a median of $176.0 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2026: Share-based Compensation climbed 23.36% in 2023, then decreased 5.13% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $145.0 million in 2022, then gained by 15.17% to $167.0 million in 2023, then increased by 11.98% to $187.0 million in 2024, then grew by 9.63% to $205.0 million in 2025, then declined by 9.76% to $185.0 million in 2026.
• Business Quant data shows MRK's Share-based Compensation at $185.0 million in Q1 2026, $205.0 million in Q4 2025, and $204.0 million in Q3 2025.